EMPIRI INC.
E-slice Technology
What we do
EMPIRI's proprietary tumor tissue slice culture, E-slice, is a novel 3D culture method that maintains the native cell:cell and cell:matrix interactions unique to an individual patient's tumor, including immune cells. Our clinically validated ex vivo assay measures therapeutic response in live tumor tissue and accurately predicts whether each individual patient will respond.
How it works
1
2
3
4
5
6
Fresh biopsy or surgical sample
Precision cut slices of tissue
Culture 4 to 8 days in defined medium
E-slice assay analysis
Primary readout
Growth curve report
Secondary readout
IHC, scRNAseq, etc.
Our tissue culture platform works with needle core biopsies or surgical samples, easily integrating into preexisting clinical workflows. With E-slice, we can test tumor biopsies against any treatment or combination of treatments in our proprietary culture conditions.
​
These results can be used to identify responders and nonresponders or they can be deployed in conjunction with additional analyses such as proteomics, scRNAseq, or IHC to extract additional biological data from each treatment arm. We can even culture E-slice for up to 30 days to meet your specific needs.
E-slice vs. the competition
Solutions for clinical research
​
The E-slice assay is a low cost, highly predictive technology that can accelerate and maximize clinical trials and drug discovery, providing empirical drug response data from a personalized therapy approach.
​
We aim to transform the cancer care continuum by optimizing the drug development pipeline with specific, empirical treatment response data. E-slice provides pharmaceutical companies with a tool that increases the efficiency of clinical trials, accelerates the validation of novel therapies, and reduces healthcare costs.
With E-slice's ability to identify effective treatments and extract biological data, it can be leveraged to
-
Identify relevant biomarkers
-
Identify optimal dosage in a faithful human avatar
-
Identify responders to enrich clinical trials
-
Study mechanisms of action and mechanisms of resistance
E-slice for clinical development
With E-slice's ability to identify effective treatments, it can be leveraged to
-
Provide data about the best treatment option for a patient
-
Identify treatments for rare or advanced cancers which lack a clear standard of care
-
Identify the most effective trial drugs for patients
E-slice as a clinical diagnostic
Service Offerings
​
We understand that your needs may vary based on the type of therapeutics you are testing and what biological insights you are most interested in.
E-slice has been validated for all solid tumor types and is compatible with chemotherapies, immunotherapies, combination therapies, ADCs, and small molecule drugs. As a 10x Genomics Certified Service Provider, we're happy to integrate spatial transcriptomics or single cell sequencing into your E-slice project as a secondary readout to the study.
​
We'd be happy to consult with you to find the right study design to compliment your needs.